An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Helia)
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Ultevursen (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Acronyms HELIA
- Sponsors ProQR Therapeutics
- 12 Dec 2022 Status changed from recruiting to discontinued.
- 18 Nov 2021 According to a ProQR Therapeutics media release, the company present data of this study at the Analyst Event via webcast.
- 18 Nov 2021 According to a ProQR Therapeutics media release, company expects to share an update from the this study by year end 2022.